Synerkine Pharma

Synerkine Pharma is a Dutch-based biotechnology startup that was founded in 2018 as a spin-off of the University Medical Center Utrecht (UMCU). The company is dedicated to the development of novel fusion proteins, known as Synerkines, with a focus on creating innovative pain solutions. These fusion proteins leverage the immunoregulatory activity of different cytokines to modulate a broad number of targets, including key elements in the pain pathway. This approach provides treatment options for chronic pain conditions with a mechanism of action that sets them apart from current analgesic drugs. With a €5.30M Series A investment received on 12 October 2023 from a consortium of investors including InnovationQuarter, Thuja Capital, Utrecht Health Seed Fund, and Flerie Invest, Synerkine Pharma is well-positioned to advance its research and development efforts in the field of pain management. The company's unique fusion proteins and their potential in addressing unmet medical needs in chronic pain treatment have drawn significant attention from investors and the healthcare industry. By leveraging innovative biotechnological solutions, Synerkine Pharma aims to bring about a paradigm shift in pain management, offering a promising avenue for addressing the challenges associated with chronic pain conditions. As it moves forward with its endeavors, the company stands to make valuable contributions to the fields of biotechnology and healthcare, offering potential for therapeutic and commercial success in the years to come.